LuminUltra is expanding its leading portfolio of molecular testing solutions with the acquisition of Genomadix. This move enhances LuminUltra’s capabilities in the rapid identification and quantification of microbes in water systems—residential, commercial, and industrial—that can cause the potentially deadly Legionnaires’ disease.
The integration includes the Genomadix Cube thermocycling platform, which, alongside an easy-to-use and automated test kit, provides results on Legionella contamination in under an hour with laboratory-level sensitivity. The user-friendly system enables on-site personnel to swiftly and accurately assess contamination levels, allowing for prompt actions to mitigate outbreak risks and minimize operational downtime.
Pat Whalen, CEO of LuminUltra, commented, “This addition significantly enhances our ability to support customers worldwide in monitoring and controlling Legionella bacteria. The Genomadix Cube offers a rapid, point-of-use solution that complements our existing GeneCount® qPCR laboratory and mail-in sample testing services. It provides a top-tier solution for on-site applications that require near real-time, precise results for making informed operational decisions.”
Steve Edgett, CEO of Genomadix, remarked, “LuminUltra is an ideal partner for the Legionella business we developed under the Spartan Bioscience brand. We are committed to ensuring a smooth transition for our customers. With LuminUltra’s scale, expertise, and focus, the Legionella business is set to grow. Genomadix will continue to advance precision medicine tests on the Cube platform and license our CubeX Open Platform to strategic partners. This agreement benefits both parties, as LuminUltra will lead the way in developing new tests and expanding access to rapid, accurate qPCR tests for critical point-of-use applications in various markets.
